TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06595017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate
Description: After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger points at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of magnesium sulphate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine (drug)
Description: After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger point at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of Lidocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger point at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of Saline
Study: NCT06593613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RUBI-A
Description: The RUBI-A intervention includes 9 sessions covering Behavioral Principles, Prevention Strategies, Visual Supports, Reinforcement, Co-Regulation, Supporting Communication, Effective Instructions, Teaching Skills, and Generalization and Maintenance. RUBI teaches skills to help build a behavioral toolbox for challenging behaviors and adaptive skills. RUBI emphasizes: 1) tailoring the intervention to the specific individual; 2) identifying behavioral function instead of topography to inform behavioral strategy choice; 3) increasing appropriate behaviors; and 4) using positive behavioral supports,39,40 such as antecedent management (e.g., use of visual supports), reinforcement, and functional communication strategies to support independence, self-help, and safety skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: R-ISLEA
Description: R-ISLEA training focuses on increasing core knowledge and understanding of autism, but it does not provide specific guidance on behavioral strategies for managing challenging behaviors. Developed by autism experts at Drexel University in collaboration with autistic self-advocates, ISLEA is a commercially available psychoeducation program designed for educators, direct support staff, families, caregivers, and autistic individuals. If English is not the language of care for a dyad, subtitles in the preferred language will be provided for the webinars, and interpreters will be available for the live sessions.
Study: NCT06588140

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duplicated refitted complete denture made from conventionally heat-cured polymethyl methacrylate.
Description: The duplication of a refitted complete removable denture will be performed using conventional heat-cured polymethyl methacrylate through the conventional heat-cured polymerization technique.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duplicated refitted complete denture made from 3D-printed CAD/CAM pink polymethylmethacrylate acrylic resin.
Description: The duplication of a refitted complete removable denture will be performed using a 3D-printed CAD/CAM technique, where the denture base is printed separately with pink polymethyl methacrylate resin, and the teeth are printed as a single unit using tooth-colored resin, followed by the assembly of the two components.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duplicated refitted complete denture made from 3D-printed CAD/CAM white polymethylmethacrylate acrylic resin.
Description: The duplication of a refitted complete removable denture will be performed using a 3D-printed CAD/CAM technique, where the denture base is printed as a single unit using tooth-colored resin, and the denture flange will be veneered with pink polymethyl methacrylate resin.
Study: NCT06596876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRG2010; Sustained-release Carbidopa/Levodopa administered placebo
Description: Subjects will receive HRG2010 and Sustained-release Carbidopa/Levodopa administered placebo administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sustained-release Carbidopa/Levodopa; HRG2010 placebo
Description: Subjects will receive Sustained-release Carbidopa/Levodopa and HRG2010 placebo administered orally.
Study: NCT06603727

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computerized Gaming Rehabilitation Program 1
Description: Brain training games displayed on a large screen paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching in place.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Gaming Rehabilitation Program 2
Description: Brain training games displayed on a tablet device paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching.
Study: NCT06597786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: Patients will receive a study kit which includes a smart watch (for monitoring of mobility / lifestyle patterns), heart rate monitor, blood pressure cuff, scale, and e-tablet. Patients may receive a treadmill to perform exercise therapy sessions. The treadmills and study kits are MSK owned equipment that will be deployed to the patients' homes and returned at the end of the study.
Study: NCT06599216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab+Dalpciclib+Standard Endocrine Therapy
Description: Adebrelimab: 1200mg, intravenously, Q4w Dalpiciclib: 150mg once a day for 3 weeks, stop for 1 week, Q4w Standard Endocrine Therapy: Choice of endocrine therapy is according to guidelines and centre policy by investigator
Study: NCT06423326

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatic Surgical Procedure
Description: Undergo surgical resection
Study: NCT06599450

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Root form dental implant
Description: Placement of titanium endosteal root form threaded tapered two-piece dental implant to assist mandibular complete overdenture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Root form dental implant
Description: Placement of titanium endosteal root form threaded tapered two-piece dental implant to assist mandibular complete overdenture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Root form dental implant
Description: Placement of titanium endosteal root form threaded tapered two-piece dental implant to assist mandibular complete overdenture
Study: NCT06590909

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Fractional CO2 laser assisted PDT
Description: Comparative split face study: participants will be treated with fractional co2 laser on the whole face then applying topical insulin on the right side of the face and topical platelet rich plasma on the left side of the face.
Study: NCT06596915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BA1302
Description: BA1302 administered intravenously
Study: NCT06602778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarkers / blood
Description: Analysis of routine biochemical parameters
Study: NCT05156684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive two placebo tablets daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive two trental tablets daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zinc
Description: Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive one zinc sulfate tablet daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zinc + pentoxifylline
Description: Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive two pentoxifylline tablets+ one zinc tablet daily
Study: NCT06306547

Intervention type: OTHER
Intervention: no interventions were involved
Description: no interventions were involved

Intervention type: OTHER
Intervention: no interventions were involved
Description: no interventions were involved
Study: NCT05857982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumab
Description: Dexamethasone 20 mg/d, on the same day of daratumumab injection; Mitoxantrone hydrochloride liposome injection: 20 mg/m2, d1; Daratumumab: 16 mg/Kg, once a week for the first 8 weeks; then changed to once every two weeks; Each cycle is 4 weeks long and the maximum number of cycles is 6.
Study: NCT06354231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DV
Description: 2.0 mg/kg, intravenously administered every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 3.0mg/kg, intravenously administered every 2 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser surgery
Description: Subjects will receive 6 cycles of DV and toripalimab, followed by laser surgery to remove ureteral or renal pelvis tumors, followed by 12 cycles of DV and 1 year of toripalimab consolidation therapy.
Study: NCT06470061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol, Quercetin, and Curcumin (RQC)
Description: 2000 mg Curcumin/day, taken twice daily for 24 months (galactomannan formulation, capsule form)~334 mg Resveratrol/day, taken twice daily for 24 months (galactomannan formulation, capsule form)~60 mg Quercetin/day, taken twice daily for 24 months (galactomannan formulation, capsule form)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Curcumin
Description: 2000 mg Curcumin/day, taken twice daily for 7 days preceding each study visit (baseline and months 3, 6, 12, 18, and 24 for a total of 42 non-consecutive days over 24 months.
Study: NCT05450094

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening Only
Description: The Screening Only intervention integrates enhancements to school-based mental health (SBMH). Each school's typical SBMH service delivery system will be enhanced with biweekly meetings of voluntary school teams (comprised of administrators, school counselors, general and special education teachers, and other school-employed mental health professionals) to 1) follow standardized evidence-based intervention decision making process to identify students with mental health risk, plan and/or refer for an evidence-based intervention, monitor intervention progress, and adjust intervention plans as needed; 2) administer teacher-rated and student self-report universal screening twice annually; 3) review screening and related school records data to identify students with mental health risk; and 4) review screening, referral, and receipt data to monitor progress of entire SBMH service delivery system.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Screening
Description: The Enhanced Screening intervention involves the enhancements to school-based mental health (SBMH) of the Screening Only intervention with the addition of 3 empirically supported enhancements: 1) Voluntary school teams will review screening and service receipt data disaggregated by racial/ethnic subgroups to identify and problem solve inequities. 2) Unintentional bias training for voluntary school teams, involving teaching participants to conceptualize prejudice as well as strategies to reduce bias. 3) Mental Health Literacy training for voluntary school teams in awareness and understanding of students' mental health well-being and need for intervention.
Study: NCT04886895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Let's Move
Description: Motor intervention
Study: NCT00057174

Intervention type: DRUG
Group type: OTHER
Intervention: Disease management of gastroesophageal reflux disease
Study: NCT06244485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valemetostat tosylate
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valemetostat tosylate
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valemetostat tosylate
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valemetostat tosylate
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valemetostat tosylate
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valemetostat tosylate
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DXd
Description: One IV infusion Q3W on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DXd
Description: One IV infusion Q3W on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DXd
Description: One IV infusion Q3W on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DXd
Description: One IV infusion Q3W on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dato-DXd
Description: One IV infusion Q3W on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dato-DXd
Description: One IV infusion Q3W on Day 1 of each 21-day cycle.
Study: NCT05983224

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: The intervention group will receive two 500 mg quercetin tablets daily, after breakfast and lunch, for twelve weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group will receive two placebo daily, after breakfast and lunch, for twelve weeks.
Study: NCT06602778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarkers / blood
Description: Analysis of routine biochemical parameters

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarkers / blood
Description: Analysis of routine biochemical parameters

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarkers / blood
Description: Analysis of routine biochemical parameters

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Physical activity level will be assessed using the International Physical Activity Questionnaire Short Form (IPQI) and sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The data to be obtained from blood will be obtained by selecting blood samples that will be sent to biological waste.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Physical activity level will be assessed using the International Physical Activity Questionnaire Short Form (IPQI) and sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The data to be obtained from blood will be obtained by selecting blood samples that will be sent to biological waste.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Physical activity level will be assessed using the International Physical Activity Questionnaire Short Form (IPQI) and sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The data to be obtained from blood will be obtained by selecting blood samples that will be sent to biological waste.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Physical activity level will be assessed using the International Physical Activity Questionnaire Short Form (IPQI) and sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The data to be obtained from blood will be obtained by selecting blood samples that will be sent to biological waste.
Study: NCT06596928

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Essential Elements T-Hero Platinum
Description: Participants will take two capsules daily for 90 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the placebo group will take two placebo capsules daily for 90 days.
Study: NCT06602154

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resin modified glass ionomer
Description: The product will be stored by investigators at room temperature in lock and key.~Product: Riva light cure RMGIC (HV) Composition: 18 mg orthodontic bonding paste and 6 ml enamel bond resin. Storage: Stored at room temperature and protected from humidity.~Usage: Steps for Resin-modified glass ionomer cement composite bonding:~1. Prepare all teeth with oil-free pumice, and rinse thoroughly for 15 seconds with water.~2. Wash thoroughly.~3. Etch enamel surface with 37% phosphoric acid for 15 seconds.~4. Rinse the etched surface for 20 seconds to remove the acid and precipitates that might have formed during the etching procedure.~5. Activate the capsule and immediately mix in an amalgamator. Do not click with applicator before you mix.~6. Immediately place into capsule applicator and click trigger until paste is seen through the nozzle~7. Light cure each increment for 20 seconds.
Study: NCT06603311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stop Treatment with Bulevertide in patients with compensated liver disease and chronic HDV infection
Description: Stop Treatment with Bulevertide in patients with compensated liver disease and chronic HDV infection who have been treated for at least 48 weeks and reached HDV RNA below 100 IU/ml for at least 24 weeks.
Study: NCT05234112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community mobilisation for hrHPV self-testing
Description: use of social media, written media, theatre and other sources of communication to reach women, and relatives, to convince them of importance of screening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community mobilisation for hrHPV self-testing
Description: use of social media, written media, theatre and other sources of communication to reach women, and relatives, to convince them of importance of screening.
Study: NCT06508385

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breathing exercise
Description: Breathing exercises will include;~1. Correct posture and sitting~2. Nose opening techniques~3. Diaphragmatic breathing, which consists of continuous and deep nasal inspiration with movement of the abdominal region and diaphragm~4. Main Breathing exercise (during 5 minutes)=inspiration (during 5 seconds) + expiration (during 15 seconds).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercise
Description: Breathing exercises will include;~1. Correct posture and sitting~2. Nose opening techniques~3. Diaphragmatic breathing, which consists of continuous and deep nasal inspiration with movement of the abdominal region and diaphragm~4. Main Breathing exercise (during 5 minutes)=inspiration (during 5 seconds) + expiration (during 15 seconds).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercise
Description: Breathing exercises will include;~1. Correct posture and sitting~2. Nose opening techniques~3. Diaphragmatic breathing, which consists of continuous and deep nasal inspiration with movement of the abdominal region and diaphragm~4. Main Breathing exercise (during 5 minutes)=inspiration (during 5 seconds) + expiration (during 15 seconds).
Study: NCT06596655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single use bronchoscope
Description: Use of single use bronchoscopes for interventional pulmonology procedures instead of reusable bronchoscopes.
Study: NCT06599177

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational leaflet
Description: An informational leaflet describing:~* Information on benefits to which they are entitled and how to receive them.~* Information and linkage to support services in the community.~* Information on how to obtain health care materials (insured, uninsured).~* Information on relevant support associations/voluntary groups in the community.~* Information on employment programs.~* Activation of patient\&#39;s supportive social network/or referral to home help programs if they are a lonely person or in need of support.~* Individualized assessment of the patient\&#39;s needs.~* Design of a plan for individualised psychosocial intervention (focus personal intervention).~* Patient education about existing social support networks in the community and how to find them.~* Educate patients about available resources in the community (benefits, services).~* Patient referral/advocacy to community services.